Logo Prima Biomed

Welcome to the Newsroom

22 November 2017

Prima Secures European Patent Grant for Lead Product IMP321 in Cancer



SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, the “Company”) announces the grant of patent number2604275 entitled “Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response” by the European Patent Office.